SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE
CLOSE HEADER
List
Professor
Professor
List
Kyun-Hwan Kim
Kyun-Hwan Kim PhD
| Graduate Program | Cancer Biology/ Infection and Immunity |
| Research Area | 분자바이러스학 |
| Laboratory | Pathogenesis Laboratory Laboratory |
| khkim10@skku.edu | |
| Tel | +82-31-299-6126 |
Education & Careers
-
1985-1991 Seoul National University, Dept. of Chemistry, B.S and M.S
1991-1999 Lotte Group R&D Center, Senior research scientist
1997-2002 Yonsei University, Dept. of Biotechnology, PhD
2003-2005 Brown University, School of Medicine, Post-Doc
2006-2019 Konkuk University, School of Medicine, Professor
2020-Now Sungkyunkwan University, School of Medicine, Professor
Research Interest
Hepatitis B virus (HBV) infection causes chronic hepatitis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC). It is a major health problem with over 350 million carriers worldwide.
Influenza, the flu, is an infectious disease caused by an influenza virus. Influenza spreads around the world in a yearly outbreak, resulting in about three to five million cases of severe illness and about 250,000 to 500,000 deaths.
The major topics of current research in my laboratory include: 1) Pathogenesis of viral infection, 2) Host immune escape of virus, 3) virus-induced liver and pulmonary diseases, 4) Development of anti-viral drugs.
Influenza, the flu, is an infectious disease caused by an influenza virus. Influenza spreads around the world in a yearly outbreak, resulting in about three to five million cases of severe illness and about 250,000 to 500,000 deaths.
The major topics of current research in my laboratory include: 1) Pathogenesis of viral infection, 2) Host immune escape of virus, 3) virus-induced liver and pulmonary diseases, 4) Development of anti-viral drugs.
Representative Research Achievements
-
1. Dezhbord M, Kim SH, Park S, et al., & Kim KH*. Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Clin Mol Hepatol. 2024 Jul30(3):539-560 (IF: 14.0).
2. Shin GC, Lee HM, Kim N, et al., & Kim KH*. PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer. Exp Mol Med. 2024 Feb 1056(1) (IF: 12.8).
3. Shin GC, Moon SU, Kang HS, et al., & Kim KH*. PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway. Nat. Commun. 2019. Jul 1810(1):3185 (IF: 17.7).
4. Park ES, Byun YH, Park S, et al., & Kim KH*. Co-degradation of interferon signaling factor DDX3 by PB1-F2 as a basis for high virulence of 1918 pandemic influenza. EMBO J. 2019. Apr 12. pii: e99475 (IF: 13.8).
5. Park ES, Lee AR, Kim DH, et al., & Kim KH*. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019. Feb 19. S0168-8278(19)30120-5 (IF: 20.582).
6. Kim DH, Park ES, Lee AR, et al., & Kim KH*. Intracellular interleukin-32γ mediates antiviral activity of cytokines against hepatitis B virus. Nat. Commun. 2018. Aug 169(1):3284 (IF: 12.353).
7. Lee AR, Lim KH, Park ES, et al., & Kim KH*. Multiple functions of cFLIP are essential for replication of hepatitis B virus. J Virol. 2018. Jul 3192(16). pii: e00339-18 (IF: 4.663).
8. Lim KH, Park ES, Kim DH, et al., & Kim KH*. Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5-UTR of TRIM22. Gut. 2017. Mar 23. pii: gutjnl-2016-312742 (IF: 23.1).
9. Shin GC, Kang HS, Lee AR, Kim KH*. Hepatitis B Virus&8211triggered Autophagy Targets Death Receptor 5 for Degradation to Limit TNFSF10/TRAIL Response. Autophagy. 2016. 12 (12):1&821116 (IF: 11.4).
10. Park YK, Park ES, Kim DH, et al., & Kim KH*. Cleaved c-FLIP mediates the antiviral effect of TNF-<alpha> against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol. 2016. Feb64(2):268-277 (IF: 20.582).